Han, Guangchun http://orcid.org/0000-0001-9277-2507
Yang, Guoliang
Hao, Dapeng
Lu, Yang http://orcid.org/0000-0001-9571-4679
Thein, Kyaw http://orcid.org/0000-0003-1518-1097
Simpson, Benjamin S. http://orcid.org/0000-0003-3685-6110
Chen, Jianfeng
Sun, Ryan
Alhalabi, Omar http://orcid.org/0000-0002-9658-2206
Wang, Ruiping
Dang, Minghao
Dai, Enyu
Zhang, Shaojun
Nie, Fengqi
Zhao, Shuangtao
Guo, Charles
Hamza, Ameer
Czerniak, Bogdan
Cheng, Chao http://orcid.org/0000-0002-5002-3417
Siefker-Radtke, Arlene
Bhat, Krishna http://orcid.org/0000-0002-2020-8509
Futreal, Andrew http://orcid.org/0000-0001-8663-2671
Peng, Guang http://orcid.org/0000-0002-4392-1497
Wargo, Jennifer http://orcid.org/0000-0003-3438-7576
Peng, Weiyi http://orcid.org/0000-0002-7785-6240
Kadara, Humam
Ajani, Jaffer http://orcid.org/0000-0001-9946-0629
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Litchfield, Kevin http://orcid.org/0000-0002-3725-0914
Ahnert, Jordi Rodon
Gao, Jianjun http://orcid.org/0000-0001-6138-4472
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Funding for this research was provided by:
Doris Duke Charitable Foundation
UT | University of Texas MD Anderson Cancer Center
Article History
Received: 23 November 2020
Accepted: 2 September 2021
First Online: 23 September 2021
Competing interests
: J.G. serves as an Advisory Committee Member for CRISPR Therapeutics, Infiniti, Jounce Therapeutics, Polaris and Seagen, as a consultant for AstraZeneca, Janssen, Pfizer, and Symphogen. J.G. is supported by the Doris Duke Clinical Scientist Development Award (#2018097), the MD Anderson Physician Scientist Award, Khalifa Physician Scientist Award, Andrew Sabin Family Foundation Fellows Award, MD Anderson Faculty Scholar Award, the David H. Koch Center for Applied Research of Genitourinary Cancers, Wendy and Leslie Irvin Barnhart Fund, and Joan and Herb Kelleher Charitable Foundation. JAW reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol–Myers Squibb. J.R.A. reports non-financial support and reasonable reimbursement for travel from European Journal of Cancer, Vall d’Hebron Institut of Oncology, Chinese University of Hong Kong, SOLTI, Elsevier, GLAXOSMITHKLINE, receiving consulting and travel fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals Inc, Pfizer, Roche Pharmaceuticals, Ellipses Pharma, NovellusDx, Ionctura and Molecular Partners (including serving on the scientific advisory board from 2015-present), receiving research funding from Blueprint Pharmaceuticals, Bayer and Novartis, and serving as investigator in clinical trials with Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, GenMab, CytomX, KELUN-BIOTECH, Takeda-Millenium, GLAXOSMITHKLINE, IPSEN and travel fees from ESMO, US Department of Defense, Louissiana State University, Hunstman Cancer Institute, Cancer Core Europe, Karolinska Cancer Institute and King Abdullah International Medical Research Center (KAIMRC), Molecular Partners. JAW serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol–Myers Squibb, Merck, Biothera Pharmaceuticals, Ella Therapeutics, and Microbiome DX. JAW also receives research support from GlaxoSmithKline, Roche/Genentech, Bristol–Myers Squibb, and Novartis, all outside of the submitted work. A.S.R. serves as an advisory board member for AstraZeneca, Bavarian Nordic, Genentech, Janssen, Merck Sharp and Dohme, Mirati, Nektar Therapeutics, and Seattle Genetics. A.S.R. receives research support from Bristol–Myers Squibb, Janssen, Merck Sharp and Dohme, Nektar Therapeutics. H.K. receives funding from Johnson and Johnson.